North America Startup Funding Rounds
Startups raising capital across North America. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 2,310 Jan 1 – Oct 26, 2026
- Disclosed funding
- $252.1B 1915 disclosed amounts
- Median round
- $23.5M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CC Celero CommunicationsCompany profile Celero develops coherent digital signal processors and analog technology for optical links that connect AI accelerators and data centers. Its validated 2nm silicon architecture is designed to move more data across scale-up, scale-out and data-center links with lower power and a path from 1.6T to next-generation 3.2T connectivity. Celero develops coherent digital signal processors and analog technology for optical links that connect AI accelerators and data centers. Its validated 2nm silicon architecture is designed to move more data across scale-up, scale-out and data-center links with lower power and a path from 1.6T to next-generation 3.2T connectivity. | $275M | Series CSeries C+ | Hardware | United States | Investors | |
| L LightsageCompany profile An agent-led growth platform measures whether AI agents can discover, evaluate and successfully use a company’s software. An agent-led growth platform measures whether AI agents can discover, evaluate and successfully use a company’s software. | $4M | FundingUndisclosed | AI | United States | Investors | |
| CI ClaimQI, Inc.Company profile Claims-intelligence software that helps health plans review and prevent improper payments against coverage rules and policy language. Claims-intelligence software that helps health plans review and prevent improper payments against coverage rules and policy language. | ~$500K | Seed | Healthtech | United States | Investors | |
| ET Encoded Therapeutics Inc.Company profile Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome. Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome. | $275M | Series FSeries C+ | Biotech | United States | Investors | |
| H HarmoniCompany profile A factory-orchestration platform connects workers, machines and business systems to coordinate production in real time. A factory-orchestration platform connects workers, machines and business systems to coordinate production in real time. | $10M | Series A | Industrial tech | United States | Investors | |
| B BleeCompany profile Blee gives legal, compliance and marketing teams an AI-assisted system to review promotional content against their rules before publication and monitor websites, social media and partner channels afterward. Blee gives legal, compliance and marketing teams an AI-assisted system to review promotional content against their rules before publication and monitor websites, social media and partner channels afterward. | $20M | Series A | Enterprise software | United States | Investors | |
| BE Bluecore EnergyCompany profile Building small nuclear reactors on floating barges for clean power to ports and nearby infrastructure Building small nuclear reactors on floating barges for clean power to ports and nearby infrastructure | $40M | Seed — additional capital within USD50m financingSeed | Climate tech | United States | Investors Silverton PartnersLeadAct One Ventures +23Animal CapitalBAG CollectiveBorusan VenturesCapital FactoryCollab CapitalFortson VCHarlem CapitalHartBeat VenturesJoel EmbiidLMnT VenturesMaC VenturesMalik MonkMarkham Valley VenturesPrecursor VenturesRackhouse Venture CapitalScribble VenturesShare VenturesSlauson & Co.Symphony VenturesTaijuan WalkerVanderbilt UniversityVisible HandsX& | |
| MB Moonwalk BiosciencesCompany profile Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027. Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027. | $70M | Series B | Biotech | United States | Investors | |
| F Fab2Company profile Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication. Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication. | $500M | Series A | Hardware | United States | Investors | |
| BB BrainChild BioCompany profile BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. | $116M | Series A | Biotech | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
BioStack, Tractian, Blacksmith
134rounds3led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
98rounds19led - 3General Catalyst
Provision Labs, Tractian, Different
71rounds7led - 4Alumni Ventures
Maxinsights, Daytona, Chariot Claims
60rounds0led - 5Khosla Ventures
Arda Industries, Tolan
59rounds6led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.